Table 4.
Emergency treatment of patients with confirmed AHF syndrome
| All patients with AHF (n=507) |
Group 1 (n=335) |
Group 2 (n=172) |
P value | |
| Furosemide | 376 (74.16%) | 252 (75.22%) | 124 (72.09%) | 0.26 |
| Oxygen | 337 (66.47%) | 225 (67.16%) | 112 (65.12%) | 0.43 |
| Nitrates | 92 (18.15%) | 71 (21.19%) | 21 (12.21%) | 0.01 |
| Anticoagulant | 37 (7.3%) | 22 (6.57%) | 15 (8.72%) | 1.00 |
| CPAP | 8 (1.58%) | 6 (1.79%) | 2 (1.16%) | 0.24 |
| NIV | 45 (8.88%) | 30 (8.96%) | 15 (8.72%) | 0.58 |
| Antiarrhythmics | 23 (4.54%) | 15 (4.48%) | 8 (4.65%) | 0.60 |
| Ionotropic agents | 3 (0.59%) | 3 (0.9%) | 0 (0%) | 0.11 |
| Tracheal intubation | 1 (0.2%) | 1 (0.3%) | 0 (0%) | 0.20 |
| None | 32 (6.31%) | 17 (5.07%) | 15 (8.72%) | 0.58 |
Data are number (%) of patients.
Group 1: patients with CRS; group 2: patients with normal renal function.
AHF, acute heart failure; CPAP, continuous positive airway pressure; CRS, cardiorenal syndrome; NIV, non-invasive ventilation.